Chemomab Therapeutics (NASDAQ:CMMB) Upgraded by Zacks Research to Strong-Buy Rating

Zacks Research upgraded shares of Chemomab Therapeutics (NASDAQ:CMMB) from a hold rating to a strong-buy rating in a research report released on Monday,Zacks.com reports.

Several other equities research analysts also recently issued reports on CMMB. Weiss Ratings reissued a “sell (e+)” rating on shares of Chemomab Therapeutics in a research report on Wednesday, October 8th. Oppenheimer raised their target price on shares of Chemomab Therapeutics from $10.00 to $25.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. Finally, Wall Street Zen raised shares of Chemomab Therapeutics to a “hold” rating in a research report on Saturday, October 11th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Chemomab Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $26.50.

Chemomab Therapeutics Stock Down 0.3%

Shares of CMMB stock opened at $3.39 on Monday. The firm has a fifty day moving average of $3.14 and a 200-day moving average of $4.19. Chemomab Therapeutics has a 12-month low of $2.39 and a 12-month high of $9.84. The company has a market capitalization of $17.53 million, a price-to-earnings ratio of -1.44 and a beta of 0.57.

Chemomab Therapeutics (NASDAQ:CMMB) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.44. On average, equities analysts expect that Chemomab Therapeutics will post -1 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Chemomab Therapeutics stock. Virtu Financial LLC grew its position in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 113.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,803 shares of the company’s stock after acquiring an additional 16,358 shares during the period. Virtu Financial LLC owned about 0.21% of Chemomab Therapeutics worth $34,000 at the end of the most recent quarter. 46.05% of the stock is currently owned by hedge funds and other institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).